28170 Neutralizing interleukin-13 increases skin microbial diversity: Results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis

Authors :: Thomas Werfel
Amy S. Paller
Andrew Pink
Mads A. Røpke
Lisa A. Beck
Anders Rosholm
Lawrence F. Eichenfield
Hidehisa Saeki
Thomas Bieber
Source :: Journal of the American Academy of Dermatology. 85:AB177
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: medicine.medical_specialty
Adult patients
business.industry
Microbial diversity
Placebo-controlled study
Dermatology
Atopic dermatitis
medicine.disease
Gastroenterology
Double blind
Internal medicine
Interleukin 13
medicine
business
Tralokinumab

Full Text Access

Tools